Kiadis Pharma pro­pos­es Robert Soiffer and Berndt Modig as its new Supervisory Board mem­bers

Amsterdam, The Netherlands, April 7, 2016 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clin­i­cal stage bio­phar­ma­ceu­ti­cal com­pa­ny devel­op­ing inno­v­a­tive T-cell immunother­a­py treat­ments for blood can­cers and inher­it­ed blood dis­or­ders, today announces that at its next General Meeting of Shareholders, the Kiadis Pharma Supervisory Board will nom­i­nate Dr. Robert Soiffer and Mr. Berndt Modig to be appoint­ed as new mem­bers of the Supervisory Board.

Dr. Robert Soiffer has worked in pro­fes­sion­al med­ical prac­tice for more than 30 years, specif­i­cal­ly in the field of hema­to­log­ic malig­nan­cies and stem cell/bone mar­row trans­plan­ta­tions. Dr. Soiffer is Professor of Medicine at the Harvard Medical School, Chief of the Division of Hematologic Malignancies at the Dana-Farber Cancer Institute (which is part of the Harvard Medical School) and Co-direc­tor of the Adult Stem Cell Transplantation Program at the Dana-Farber Cancer Institute. Dr. Soiffer is Chair Elect of the Advisory Committee of the Center for International Blood and Marrow Transplant Research (CIBMTR), serves on the Board of Directors for the National Marrow Donor Program Be the Match Registry and has served as President of the American Society of Blood and Marrow Transplantation (ASBMT). Dr. Soiffer grad­u­at­ed from the New York University School of Medicine and com­plet­ed his res­i­den­cy in inter­nal med­i­cine at Brigham and Women’s Hospital where he was also Chief Medical Resident before join­ing the Dana-Farber Cancer Institute, after com­plet­ing a med­ical oncol­o­gy fel­low­ship.

Mr. Berndt Modig has more than 30 years of pro­fes­sion­al inter­na­tion­al expe­ri­ence in finance, includ­ing oper­a­tions man­age­ment and audit com­mit­tee roles. He has served as Chief Financial Officer of Prosensa Holding N.V. and as Chief Financial Officer at Jerini AG. Mr. Modig is cur­rent­ly serv­ing on the boards of Axovant Sciences Ltd., Auris Medical AG and Affimed N.V. and is CEO of Pharvaris B.V. Mr. Modig holds a bachelor’s degree in busi­ness admin­is­tra­tion, eco­nom­ics and German from the University of Lund, Sweden and an M.B.A. degree from INSEAD, Fontainebleau, France and is a Certified Public Accountant.

Mark Wegter, Chairman of the Supervisory Board of Kiadis Pharma, com­ment­ed: “We are delight­ed to wel­come both Robert and Berndt to our Supervisory Board. They are both high­ly respect­ed, well con­nect­ed pro­fes­sion­als with very rel­e­vant expe­ri­ence. Their exper­tise gained from work­ing with­in the biotech­nol­o­gy and phar­ma­ceu­ti­cal sec­tors across both Europe and the US will be invalu­able to Kiadis Pharma as we con­tin­ue to build momen­tum fol­low­ing the recent announce­ment of pos­i­tive results on the pri­ma­ry end­point of our Phase II tri­al with our lead prod­uct ATIR101™.”

Leave a Reply

Your email address will not be published. Required fields are marked *